This Tender Offer Statement on Schedule TO relates solely to preliminary communications made before the
commencement of a planned tender offer for all outstanding shares of Class A Common Stock, par value $0.01 per share, and Class B Common Stock, par value $0.01 per share, of Rapid Micro Biosystems, Inc., a Delaware corporation
(“Rapid”), by EMD Holdings NewCo II, Inc, a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany, a German corporation with general partners (“Parent”) to be commenced
pursuant to the Agreement and Plan of Merger, dated as of November 16, 2026, by and among Rapid, Parent and Purchaser.
Additional Information and
Where to Find It
The tender offer described in this communication has not yet commenced, and this communication is neither an offer to purchase nor a
solicitation of an offer to sell securities. At the time the tender offer is commenced, Parent and Purchaser will file a tender offer statement on Schedule TO with the U.S. Securities and Exchange Commission (the “SEC”), and Rapid will
file a solicitation/recommendation statement on Schedule 14D-9 with the SEC. INVESTORS AND SECURITY HOLDERS ARE STRONGLY ADVISED TO READ THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, LETTER OF
TRANSMITTAL AND RELATED TENDER OFFER DOCUMENTS) THAT WILL BE FILED BY PARENT AND PURCHASER WITH THE SEC AND THE RELATED SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 THAT WILL BE FILED BY RAPID WITH
THE SEC, WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. These materials (once they become available) will be made available to Rapid shareholders at no cost by the information agent for the tender offer. Once filed,
these documents will be available at no charge on the SEC’s website at www.sec.gov. In addition, a copy of the offer to purchase, letter of transmittal and certain other related tender offer documents (once they become available) may be
obtained free of charge from Parent under the “Investors” section of Parent’s website at https://www.emdgroup.com/en. A copy of the solicitation/recommendation statement (once it becomes available) also may be obtained free of
charge from Rapid under the “Investor Relations” section of Rapid’s website at https://www.rapidmicrobio.com/.
Forward Looking
Statements
This Tender Offer Statement includes “forward-looking statements” regarding the potential acquisition of Rapid. All statements,
other than statements of historical fact, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “outlook,” “aim,” “anticipate,” “assume,”
“believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,”
“plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other words and terms of similar meaning.
Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned
not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties.
Risks and uncertainties include, but are not limited to: the risk that the closing conditions for the proposed acquisition will not be satisfied; uncertainty
as to the percentage of Rapid shareholders that will support the proposed acquisition and tender their shares in the offer; the risk of shareholder litigation relating to the proposed acquisition, including resulting expense or delay; the
possibility that the proposed acquisition will not be completed in the expected timeframe or at all; potential adverse effects to the businesses of Parent or Rapid during the pendency of the proposed acquisition, such as employee departures or
distraction of management from business operations; the potential that the expected benefits and opportunities of the proposed acquisition, if completed, may not be realized or may take longer to realize than expected; the occurrence of any event,
change or other circumstance that could give rise to the termination of the merger agreement and potential adverse reactions or changes to business relationships resulting from the proposed acquisition, including the effect of the acquisition on the
ability to maintain key vendor, supplier or partner relationships; and risks related to the integration of Rapid into Parent subsequent to the closing of the proposed acquisition and the timing of such integration.
A further list and descriptions of these risks, uncertainties and other factors can be found in Parent’s public reports which are available on the
Parent’s website at https://www.emdgroup.com/en. Parent is not under any obligation, and expressly disclaims any obligation, to update or otherwise revise any forward-looking statements, whether as a result of new information, future events,
or otherwise.